RecruitingPhase 3NCT07491445

Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma

RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel Versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma

Sponsor

Revolution Medicines, Inc.

Enrollment

900 participants

Start Date

Mar 9, 2026

Study Type

INTERVENTIONAL

Conditions

Pancreatic Cancer Pancreatic Ductal Adenocarcinoma (PDAC)Pancreatic Adenocarcinoma Metastatic Pancreatic Adenocarcinoma PDAC PDAC - Pancreatic Ductal Adenocarcinoma Pancreatic Cancer Metastatic Pancreatic Adenosquamous Carcinoma

Summary

The purpose of this study is to evaluate the safety and efficacy of an investigational RAS(ON) inhibitor administered as monotherapy or in combination with chemotherapy, compared with standard of care (SOC) chemotherapy alone.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called daraxonrasib, a drug called gemcitabine, and others for people with pdac, pdac - pancreatic ductal adenocarcinoma, and other related conditions. The study is currently recruiting participants at 13 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGdaraxonrasib

oral tablets

DRUGgemcitabine

intravenous (IV) infusion

DRUGnab-paclitaxel

IV infusion

Locations(20)

Honor Health Research Institute

Scottsdale, Arizona, United States

H Lee Moffitt Cancer Center and Research Institute

Tampa, Florida, United States

Johns Hopkins Sidney Kimmel Comprehensive Cancer Center

Baltimore, Maryland, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Comprehensive Cancer Centers of Nevada

Henderson, Nevada, United States

Memorial Sloan Kettering Cancer Center

New York, New York, United States

University of Cincinnati Cancer Center

Cincinnati, Ohio, United States

Taylor Cancer Research Center

Maumee, Ohio, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

SCRI - Texas Oncology Dallas

Dallas, Texas, United States

MD Anderson Cancer Center

Houston, Texas, United States

Virginia Cancer Specialists

Fairfax, Virginia, United States

Virginia Mason Medical Center

Seattle, Washington, United States

Calvary Mater Newcastle

Waratah, New South Wales, Australia

National Cancer Center - East

Kashiwa, Chiba, Japan

Cancer Institute Hospital - Japan Foundation for Cancer Research

Koto-Ku, Tokyo, Japan

NHO Kyushu Cancer Center

Fukuoka, Japan

Kanagawa Cancer Canter

Kanagawa, Japan

Wakayama Medical University Hospital

Wakayama, Japan

Yamaguchi University Hospital

Yamaguchi, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07491445

Related Trials

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors

NCT0706665720 locations

WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

NCT062913241 location

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

NCT0727741316 locations

IDOV-Immune for Advanced Solid Tumors

NCT069106575 locations

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

NCT0520876262 locations